Nature Cancer

Article	Citations
Enhancing childhood cancer targetability	738
An oncolytic circular RNA therapy	599
Considering molecular alterations as pan-cancer tissue-agnostic targets	442
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	408
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	355
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	352
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	322
Gut decisions in CAR T cell therapy	314
MALAT1 protects dormant tumor cells from immune elimination	269
Breaking frontiers with multidisciplinary cancer research	254
A low-coverage liquid biopsy for lung cancer	209
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study	205
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	203
A macrophage-activated abscopal effect	181
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	167
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	162
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	162
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	153
Shooting for multiplexed pathology with Orion	148
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	148
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	144
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial	144
The cGAS–STING pathway and cancer	140
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	140
Expanding the options for KRAS inhibition	137

Palmitate oxidation drives a pro-metastatic post-translational modification	137
A molecular glue halts RAS–MAPK signaling	134
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	134
The importance of being generous	131
Bone marrow progenitor-like cells against leukemia cure	127
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial	123
Shaping the microenvironment in peritoneal metastases	122
Determinants of resistance and response to melanoma therapy	120
Advancing therapeutics in small-cell lung cancer	115
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	115
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	114
Stress granules shape metabolic reprogramming and drug resistance	114
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	113
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	113
Impact of context-dependent autophagy states on tumor progression	113
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	111
Sarcoma ecotypes determine immunotherapy benefit	110
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	110
Antibody avidity meets multiple myeloma	107
Key insights from ESMO Congress 2025	103
Innate immunity drives epithelial cell plasticity during prostate tumor formation	101
Thriving in diverse ecosystems	101
Inflammation meets translation in AML	101
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	97
Evolving landscape of nasopharyngeal carcinoma therapy	94
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	94
A comeback for checkpoint inhibition in multiple myeloma	93
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche	93
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial	93
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	92
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	92
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	91
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	91
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	91
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	90
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	90
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	90
Cycling back to folate metabolism in cancer	89
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	89
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	89
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	88
Multimodal data integration improves immunotherapy response prediction	86
Immunotargeting of a recurrent AML-specific neoantigen	85
Dual inhibition of EGFR and PI3K with a single drug	85
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	84
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	84
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	82
Radioligand cancer therapy comes to the fore	82
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	82
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	81

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	80
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics	78
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	77
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	77
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	75
How AI agents will change cancer research and oncology	75
Local sensory innervation shapes anti-tumor immunity in lung cancer	74
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	73
Building a translational cancer dependency map for The Cancer Genome Atlas	72
Selective targeting of malignant T cells	71
Bispecific chimeric T cell receptors tackle tumor heterogeneity	70
Regional delivery of hypoxia-responsive CAR T cells improves efficacy for solid tumors	70
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	69
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	67
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	67
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	67
Mesenchymal tumor features predict response to immune-checkpoint blockade in glioblastoma	67
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	67
Highlights from the 2025 ASCO Annual Meeting	67
A polyadenylation enzyme rewires metabolism to fuel AML	64
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	63
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	63
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer	63
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	63
Dalpiciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial	62
Epigenetic plasticity in PDAC	61
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	61
Anything to declare?	61
Advances in antibody-based therapy in oncology	61
The tumor microenvironment’s role in the response to immune checkpoint blockade	61
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	59
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	59
An unexpected career in cancer metabolism	59
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	58
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	58
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	58
Neoadjuvant immunotherapy marks a new era in oncology	57
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	57
In vivo macrophage engineering for renal cancer therapy	57
Ricolinostat is not a highly selective HDAC6 inhibitor	57
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	56
Myeloma evades T cell-engaging therapies	56
Metabolic symbiosis in pancreatic cancer	55
Clinical and translational attributes of immune-related adverse events	55
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	55
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	54
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	54
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	54
p53 at the crossroads of tumor immunity	53
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	52
M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors	52
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	52
CD8+ T cell killing of MHC class I–deficient tumors	52
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	52
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	51
Masking T cell engagers mitigates on-target off-tumor activity	50
Understanding the biology of lung cancer brain metastases	50
CAR T cell therapy: looking back and looking forward	50
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p	49
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	49
Breaking the performance ceiling for neoantigen immunogenicity prediction	48
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	48
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	48
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	48
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	47
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial	46
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	46
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	45
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	45
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	45
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	45
Leukemic and normal hematopoietic stemness is influenced by transposable elements	44
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	44
GABA shapes GBM immune responses in a sex-dependent manner	44
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	44
Communicating with respect	43
Radiopharma pipeline builds ahead of key data	43
The meaning of impact	43
Near-infrared optogenetic engineering of bacteria for cancer therapy	42
A 180 degree turn en route to crafting a scientific career that never goes stale	41

Insight from the ESMO Targeted Anticancer Therapies Congress 2025	41
Leptomeningeal metastatic cancer cells induce a permissive choroid plexus vasculature through extracellular-vesicle-derived 5-HIAA signaling	41
Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan	41
CD4+ CAR T cells — more than helpers	40
Leveraging the potential for deintensification in cancer care	40
Artificial intelligence for prostate cancer diagnostics	40
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	39
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	39
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results	39
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	39
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	38
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	38
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	37
Cellular neighborhoods in cancer	37
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial	37
Glucagon-like peptide-1 medicines and cancer	37
Leveraging translational insights toward precision medicine approaches for brain metastases	37
Disparities, aging and childhood cancer	36
Commensal metabolite boosts chemotherapy	36
CDK10 inhibits innate sensing to constrain antitumor immunity	35
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	35
Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence	35
Fibrotic tumors tune metabolism for immune evasion	35
The aging lung reawakens dormant tumor cells	35
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	34
Harnessing foundation models for digital pathology without re-training	34
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	34
Targeting HIF-1 to treat AML	34
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	34
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	34
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	34
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis	33
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	33
Bicarbonate transport as a vulnerability in pancreatic cancer	33
The landscape of T cell antigens for cancer immunotherapy	33
Not a generative AI–generated Editorial	33
The growing threat of cyberwarfare in cancer healthcare	33
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	33
Androgen loss contributes to neuroinflammation and promotes brain tumor growth	33
CAR T cell therapy for multiple myeloma	33
Checkpoint blockade regulates T cell fate by supporting co-stimulation	32
Checking immunotoxicity risks of checkpoint blockade	32
T cells lead the charge against solid tumors	32
LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells	32